Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab.
Infliximab is an antibody to tumor necrosis factor (TNF) that is used in the treatment of Crohn disease and rheumatoid arthritis. This medication neutralizes TNF-alpha by binding to TNF receptors and inhibiting further induction of proinflammatory cytokines. We describe a patient with Crohn disease who developed hypersensitivity vasculitis with biopsy-proven leukocytoclastic vasculitis 9 days after her initial dose of infliximab. To our knowledge, this is the first reported case of infliximab-induced hypersensitivity vasculitis with leukocytoclastic vasculitis that occurred after the first dose of drug. It is important to note that hypersensitivity vasculitis can occur secondary to administration of this drug, even after the initial exposure.
McIlwain
Laura
L
Department of Rheumatology, University of South Florida College of Medicine, Tampa 33612, USA.
Carter
John D
JD
Bin-Sagheer
Syed
S
Vasey
Frank B
FB
Nord
Juergen
J
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D004342:Drug Hypersensitivity / Q000209:etiology*; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008297:Male; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab